Skip to main content

Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Ziel

HYPOTHESIS: Early inhalation of Budesonide (BS) reduces the absolute risk of developing bronchopulmonary dysplasia (BPD) or death in preterm infants born between 23 and 27 weeks gestational age (GA) by 10%. PRIMARY OBJECTIVE: Survival without BPD at 36 weeks GA. SECONDARY OBJECTIVES: (1) neurodevelopment at a corrected age of 18-22 months; (2) adverse treatment effects; (3) mortality at 36 weeks GA; (4) BPD incidence at 36 weeks GA; (5) duration of positive pressure respiratory support or supplemental oxygen; (6) pharmacokinetic-pharamacodynamic analyses. RATIONALE: Inflammation is central to the development of BPD. Corticosteroids (CS) have antiinflammatory properties and early inhalation of CS may allow for beneficial local effects on the pulmonary system with a lower risk of undesirable systemic side effects. STUDY DESIGN: Randomised placebo-controlled, multi-centre clinical trial and genetic/pharmacogenetic substudy. RESEARCH PLAN: Within 2 years 850 infants of 23-27 weeks GA will be randomised during the first 12 hours of life to BS or placebo to prevent BPD. Study drugs will be administered via Aerochamber and continued until infants are either off supplementary oxygen and positive pressure support or have reached a GA of 32 0/7 weeks regardless of ventilatory status. Study patients will be followed and neurodevelopmental outcomes will be assessed at a corrected age of 18-22 months. CLINICAL SIGNIFICANCE: BPD contributes to the mortality of preterm infants and is associated with impaired neurosensory development and an increased risk of pulmonary morbidity in adolescence and young adulthood. Systemic CS are effective in preventing BPD, but their use is practically prohibited given their adverse effects on neurodevelopment. Early inhalation of CS has been shown to be associated with secondary pulmonary benefits, but its effect on survival without BPD and on neurodevelopment remains unclear.

Wissenschaftliches Gebiet

  • /Sozialwissenschaften/Soziologie/Demografie/Sterblichkeit

Aufforderung zur Vorschlagseinreichung

FP7-HEALTH-2007-B
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

CP-FP - Small or medium-scale focused research project
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Koordinator

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Adresse
Geschwister-scholl-platz
72074 Tuebingen
Deutschland
Aktivitätstyp
Higher or Secondary Education Establishments
EU-Beitrag
€ 2 535 032,52
Kontakt Verwaltung
Christian Poets (Prof.)

Beteiligte (14)

BELFAST HEALTH AND SOCIAL CARE TRUST

Beteiligung beendet

United Kingdom
Adresse
Lisburn Road Belfast City Hospital A Floor
BT9 7AS Belfast
Aktivitätstyp
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Kontakt Verwaltung
Ian Young (Prof.)
UNIVERZITA KARLOVA
Tschechien
EU-Beitrag
€ 350 886,80
Adresse
Ovocny Trh 560/5
116 36 Praha 1
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Kristyna Matejkova
OULUN YLIOPISTO
Finnland
EU-Beitrag
€ 681 470
Adresse
Pentti Kaiteran Katu 1
90014 Oulu
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Arto Eljander (Mr.)
CLALIT HEALTH SERVICES
Israel
EU-Beitrag
€ 435 276,80
Adresse
Arlozorov Street 101
62098 Tel Aviv
Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Haim Keren (Mr.)
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
Frankreich
EU-Beitrag
€ 391 086,80
Adresse
3 Avenue Victoria
75000 Paris
Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Christophe Misse
Azienda Ospedaliero Univesitaria Ospedali Riuniti Umberto I- G.M. Lancisi- G. Salesi
Italien
EU-Beitrag
€ 392 046,80
Adresse
Via Conca 71
60126 Ancona
Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Virgilio Carnielli (Prof.)
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Niederlande
EU-Beitrag
€ 147 156,80
Adresse
Dr Molewaterplein 40
3015 GD Rotterdam
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Annemieke Steenbergen (Dr.)
ROBERT BOSCH GESELLSCHAFT FUR MEDIZINISCHE FORSCHUNG MBH
Deutschland
EU-Beitrag
€ 86 536,80
Adresse
Auerbachstrasse 112
70376 Stuttgart
Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Christiane Schmiedl (Ms.)
POHJOIS-POHJANMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMA
Finnland
EU-Beitrag
€ 86 560
Adresse
Kajaanintie 50
90220 Oulu
Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Mikko Hallman (Prof.)
ARISTOTELIO PANEPISTIMIO THESSALONIKIS

Beteiligung beendet

Greece
EU-Beitrag
€ 11 300,68
Adresse
Kedea Building, Tritis Septemvriou, Aristotle Univ Campus
54636 Thessaloniki
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Georgia Petridou (Ms.)
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Deutschland
EU-Beitrag
€ 46 400
Adresse
Robert-koch-strasse 40
37075 Goettingen
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Christiane Hennecke (Ms.)
TECHNISCHE UNIVERSITAET DRESDEN
Deutschland
EU-Beitrag
€ 136 960
Adresse
Helmholtzstrasse 10
01069 Dresden
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Carsten Glueck (Mr.)
ASSOCIATION HOSPITALIERE DE BRUXELLES-CENTRE HOSPITALIER UNIVERSITAIRE SAINT PIERRE
Belgien
EU-Beitrag
€ 232 700
Adresse
Rue Haute 322
1000 Bruxelles
Aktivitätstyp
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Kontakt Verwaltung
Patrice Buyck (Mrs.)
University of Zurich
Schweiz
EU-Beitrag
€ 90 000
Adresse
Ramistrasse 71
8006 Zurich
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Dirk Bassler (Prof.)